PetMed Express Reports 21.1% Revenue Decline and Increased Net Loss for Fiscal Year Ending March 31, 2026

PetMed Express, Inc., a leading online pet pharmacy, reported a significant decline in financial performance for the fiscal year ending March 31, 2026. The company generated total revenues of approximately $179.0 million, a decrease of 21.1% from $227.0 million in the previous fiscal year. This decline was primarily attributed to a drop in prescription medication sales, which accounted for a substantial portion of the company's revenue. The net loss for the year increased to approximately $57.3 million, compared to a loss of $6.3 million in the prior year, largely due to a $26.7 million goodwill impairment charge and increased operational costs.

In terms of operational metrics, PetMed Express reported a decrease in customer acquisition, with approximately 266,000 new customers added in fiscal 2026, down from 351,000 in fiscal 2025. The average order value remained relatively stable, increasing slightly from $97 to $98 year-over-year. The company also noted that recurring sales, including its AutoShip subscription program, represented 62.6% of total gross sales in the most recent quarter, up from 56.1% in the same quarter of the previous year, indicating a positive trend in customer retention and engagement.

Strategically, PetMed Express expanded its product offerings through the acquisition of PetCareRx in April 2023, which allowed the company to enhance its catalog with additional non-prescription products, including pet food and supplies. This acquisition aimed to diversify revenue streams and improve distribution capabilities. However, the integration of PetCareRx has not yet fully mitigated the challenges faced by the company, as evidenced by the ongoing operational losses and the need for strategic cost reductions.

Looking ahead, PetMed Express has outlined a plan to address its financial challenges, focusing on optimizing advertising spend, reducing operating expenses, and enhancing its technology infrastructure. The company has also suspended its quarterly dividend indefinitely to conserve cash for growth initiatives. Management expressed confidence that these measures would alleviate concerns regarding the company's ability to continue as a going concern, despite the substantial doubt raised by declining cash balances and ongoing losses.

Overall, PetMed Express is navigating a challenging market environment characterized by increased competition and changing consumer behaviors. The company's future performance will depend on its ability to effectively implement its strategic initiatives and adapt to the evolving landscape of the pet healthcare industry.